Tapentadol
Pronunciation: (ta-PEN-ta-dol).
- Generic name
- Tapentadol
- Brand names
- Tydol, Nucynta, Palexia SR, Tapenta, Nucynta ER, Palexia
- Drug class
- Opioid Analgesic
Availability and supply rules vary by country
Trade names by country: United States · Canada
Australia: · Full directory
What Tapentadol is and how it works
Uses, formulations, monitoring, and supply rules can differ by patient, product, and country. Follow the exact local product information and professional advice.
Mechanism of action: how Tapentadol works
Tapentadol is a centrally acting analgesic with a dual mechanism: it is a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor. The opioid agonist action provides traditional opioid analgesia, while norepinephrine reuptake inhibition enhances descending pain inhibition pathways. This dual action differentiates tapentadol from classical opioids and may contribute to its efficacy in both nociceptive and neuropathic pain. (1)
What Tapentadol is used for
Moderate to severe acute pain
Moderate to severe acute pain (1)
Moderate to severe chronic pain
Moderate to severe chronic pain (1)
Neuropathic pain associated with diabetic peripheral neuropathy
Neuropathic pain associated with diabetic peripheral neuropathy (1)
Before taking Tapentadol
Do not take / not appropriate for
- severe respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction (including paralytic ileus), and hypersensitivity to tapentadol. (Contraindication) (1)
Tell your clinician about
(1)How to take Tapentadol
- General Instructions: Take tapentadol exactly as prescribed by your healthcare provider. Do not take more than the recommended dose or use it for longer than directed.. Adult Dosing: For acute pain (immediate-release): 50–100 mg orally every 4–6 hours as needed. Maximum daily dose is typically 600 mg for acute pain. For chronic pain (extended-release): Initial dose is 50 mg twice daily, titrated as needed. Maximum daily dose is 500 mg for chronic pain.. Pediatric Dosing: Tapentadol is not recommended for use in children or adolescents under 18 years of age.. Administration: Swallow tablets whole with water. Do not crush, chew, or split extended-release tablets. Take with or without food, but take consistently with respect to meals.. When To Stop: Do not stop tapentadol suddenly without consulting your doctor, as withdrawal symptoms may occur. Your doctor will guide you on how to taper the dose safely.. Storage: Store at room temperature (68–77°F or 20–25°C), away from moisture, heat, and light. Keep out of reach of children and pets.
- This page does not provide a dose calculator. Dosing must follow the prescriber, pharmacist, or product label.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (1)
Missed dose
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and resume your regular schedule. Do not take two doses at once.
Overdose
In case of overdose, seek emergency medical help immediately. Symptoms may include extreme drowsiness, slow or difficult breathing, loss of consciousness, or coma. Overdose can be fatal, especially in children or those not used to opioids. (1)
Side effects
Side effects and their urgency vary; report severe, persistent, or concerning symptoms to a healthcare professional.
Nausea
Incidence: Reported in the clinician-authored database; frequency not established
Dizziness
Incidence: Reported in the clinician-authored database; frequency not established
Constipation
Incidence: Reported in the clinician-authored database; frequency not established
Somnolence
Incidence: Reported in the clinician-authored database; frequency not established
Vomiting
Incidence: Reported in the clinician-authored database; frequency not established
Respiratory depression
Incidence: Reported in the clinician-authored database; frequency not established
Serotonin syndrome
Incidence: Reported in the clinician-authored database; frequency not established
Serious warnings
FDA BOXED WARNING — Addiction, Abuse, and Misuse — serious
Symptoms: FDA BOXED WARNING — Addiction, Abuse, and Misuse: tapentadol exposes users to risks of addiction, abuse, and misuse, which can lead to overdose and death. Life-Threatening Respiratory Depression: serious, life-threatening, or fatal respiratory depression may occur, especially at initiation or after a dose increase; proper dosing and titration are essential. Interaction with Benzodiazepines or Other CNS Depressants: concomitant use with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death — reserve concomitant prescribing for patients with no adequate alternative. Accidental Ingestion: accidental ingestion of tapentadol, especially by children, can result in a fatal overdose. Neonatal Opioid Withdrawal Syndrome: extended opioid use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated; delivery should be planned where neonatology expertise is available.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (1)
Tapentadol can cause serious, life-threatening respiratory depression (see FDA boxed warning above) — serious
Symptoms: Tapentadol can cause serious, life-threatening respiratory depression (see FDA boxed warning above). Risk of addiction, abuse, and misuse is present. May cause withdrawal symptoms if stopped abruptly. Not recommended during pregnancy or breastfeeding unless clearly needed. Use caution in elderly patients and those with liver or kidney impairment.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (1)
Contraindications recorded in the clinician database — serious
Symptoms: Contraindications recorded in the clinician database: Contraindications include severe respiratory depression, acute or severe bronchial asthma, known or suspected gastrointestinal obstruction (including paralytic ileus), and hypersensitivity to tapentadol. Use with caution in patients with a history of substance use disorder, head injury, increased intracranial pressure, hepatic or renal impairment, elderly, and those taking other CNS depressants.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (1)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Recorded interactions | Tapentadol may interact with other medications that depress the central nervous system, such as benzodiazepines, other opioids, alcohol, antipsychotics, and sedatives. Combining tapentadol with monoamine oxidase inhibitors (MAOIs) or serotonergic drugs increases the risk of serotonin syndrome. Always inform your healthcare provider about all medicines and supplements you are taking. | (1) |
Pregnancy, breastfeeding, kidney/liver function, age
Pregnancy
Prolonged opioid use during pregnancy can cause neonatal opioid withdrawal syndrome (see boxed warning). Available human data with tapentadol are insufficient to establish a drug-associated risk of major birth defects or miscarriage; in animal studies, embryo-fetal death and structural malformations occurred with tapentadol given to rabbits during organogenesis, and skeletal development was delayed in rats. Discuss any pregnancy or plans for pregnancy with your prescriber. (1)
Breastfeeding
There is no data on tapentadol levels in human breast milk, its effects on a breastfed infant, or its effects on milk production; tapentadol is present in animal milk, and when a drug is present in animal milk it is likely also present in human milk. Infants exposed to tapentadol through breast milk should be monitored for excess sedation and breathing problems, and withdrawal symptoms can occur in a breastfed infant if the mother's opioid use or breastfeeding is stopped. Discuss breastfeeding with your prescriber, who can weigh the benefits of breastfeeding against your clinical need for tapentadol. (1)
Children
Frequency: Not applicable for chronic-pain extended-release use (adults only). Weight Based: Immediate-release tapentadol is approved for acute pain in pediatric patients 6 years and older weighing at least 40 kg, using weight- and age-based dosing set by the prescriber — this page does not provide that pediatric dosing table.. Max Daily Dose: Not established on this page for pediatric use; follow the prescriber's specific regimen.. Max Single Dose: Not established on this page for pediatric use.. Age Restrictions: Not recommended in children under 6 years, or in pediatric patients with hepatic or renal impairment at any age. (1)
Renal Impairment
Hepatic: no dosage adjustment is needed for mild hepatic impairment (Child-Pugh score 5-6). For moderate hepatic impairment (Child-Pugh score 7-9), start at 50 mg no more than once every 8 hours (maximum 3 doses in 24 hours), then adjust the dosing interval based on pain control and tolerability, with regular monitoring for respiratory and CNS depression. Tapentadol has not been studied in, and is not recommended for, severe hepatic impairment (Child-Pugh score 10-15). Renal: exposure to tapentadol itself is similar across normal to severely impaired kidney function, but exposure to its glucuronide metabolite rises substantially with worsening renal impairment (about 1.5-, 2.5-, and 5.5-fold higher in mild, moderate, and severe impairment respectively); tapentadol is not recommended in severe renal impairment. Tapentadol has not been studied in pediatric patients with hepatic or renal impairment of any degree, and use in that group is not recommended. (1)
Hepatic Impairment
Hepatic: no dosage adjustment is needed for mild hepatic impairment (Child-Pugh score 5-6). For moderate hepatic impairment (Child-Pugh score 7-9), start at 50 mg no more than once every 8 hours (maximum 3 doses in 24 hours), then adjust the dosing interval based on pain control and tolerability, with regular monitoring for respiratory and CNS depression. Tapentadol has not been studied in, and is not recommended for, severe hepatic impairment (Child-Pugh score 10-15). Renal: exposure to tapentadol itself is similar across normal to severely impaired kidney function, but exposure to its glucuronide metabolite rises substantially with worsening renal impairment (about 1.5-, 2.5-, and 5.5-fold higher in mild, moderate, and severe impairment respectively); tapentadol is not recommended in severe renal impairment. Tapentadol has not been studied in pediatric patients with hepatic or renal impairment of any degree, and use in that group is not recommended. (1)
Monitoring
(1)Storage
Store at 20-25°C (68-77°F); brief excursions between 15-30°C (59-86°F) are permitted. Protect from moisture. Because of the risk of accidental ingestion, misuse, and abuse, store tapentadol securely, out of sight and reach of children and others, including visitors to the home, and dispose of unused medicine promptly and properly.
Professional information
Clinician-facing context only. This section does not replace current product labeling.
General
Indication: Moderate to severe acute pain
Dose summary: Initial dose: 50 mg to 100 mg orally every 4 to 6 hours as needed for pain.
Renal context: The FDA label states that exposure to tapentadol itself is comparable across normal to severely impaired renal function, but exposure to its glucuronide metabolite increases substantially with worsening renal impairment (about 1.5-, 2.5-, and 5.5-fold higher in mild [CrCl 50-<80 mL/min], moderate [CrCl 30-<50 mL/min], and severe [CrCl <30 mL/min] impairment respectively). Severe renal impairment is not recommended for tapentadol use. (1)
Hepatic guidance
The FDA label states no dosage adjustment is needed for mild hepatic impairment (Child-Pugh score 5-6). For moderate hepatic impairment (Child-Pugh score 7-9), initiate treatment with 50 mg no more frequently than once every 8 hours (maximum 3 doses in 24 hours), then adjust the dosing interval to maintain analgesia with acceptable tolerability, with regular evaluation for respiratory and CNS depression. Tapentadol has not been studied in, and use is not recommended for, severe hepatic impairment (Child-Pugh score 10-15).
Frequently asked questions
What is tapentadol used for?
Tapentadol is used to treat moderate to severe pain in adults, including acute pain (such as after surgery) and chronic pain conditions like neuropathic pain associated with diabetes.
How does tapentadol work?
Tapentadol works by binding to opioid receptors in the brain and spinal cord and by inhibiting the reuptake of norepinephrine, which together help reduce the perception of pain.
Is tapentadol addictive?
Yes, tapentadol has a risk of addiction, abuse, and misuse, especially with prolonged use. Always take it exactly as prescribed and discuss any concerns with your doctor.
Can I drink alcohol while taking tapentadol?
No, you should avoid alcohol while taking tapentadol. Alcohol increases the risk of dangerous side effects, including severe drowsiness, respiratory depression, and overdose.
What should I do if I miss a dose?
Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue your regular schedule. Do not double up doses.
Can tapentadol be used in children?
Tapentadol is not recommended for use in children or adolescents under 18 years of age due to lack of safety and efficacy data.
What are the signs of overdose?
Signs of overdose include extreme drowsiness, slow or shallow breathing, loss of consciousness, and unresponsiveness. Seek emergency medical help immediately if overdose is suspected.
What happens if I take too much Tapentadol?
Taking too much Tapentadol can lead to a serious overdose, characterized by symptoms such as severe drowsiness, slowed breathing, pinpoint pupils, and loss of consciousness. An overdose is a medical emergency. If you suspect an overdose, seek immediate emergency medical help by calling 911 or your local emergency number.
Is Tapentadol safe during pregnancy?
Tapentadol's safety during pregnancy is not fully established, and it is generally recommended to consult your doctor. Opioid use during pregnancy can lead to neonatal opioid withdrawal syndrome in the newborn. Your healthcare provider can assess the potential risks and benefits, and discuss alternative pain management strategies if necessary, to ensure the well-being of both mother and baby.
What is the mechanism of action of Tapentadol?
Tapentadol is a centrally acting analgesic with a dual mechanism: it is a mu-opioid receptor agonist and a norepinephrine reuptake inhibitor. The opioid agonist action provides traditional opioid analgesia, while norepinephrine reuptake inhibition enhances descending pain inhibition pathways. This dual action differentiates tapentadol from classical opioids and may contribute to its efficacy in both nociceptive and neuropathic pain. (1)
What is the generic name of Tapentadol?
The generic name is Tapentadol. It is sold under brand names including Tydol, Nucynta, Palexia SR, Tapenta, Nucynta ER, Palexia.
What class of drug is Tapentadol?
Tapentadol is classed as: Opioid Analgesic.
References
- UNRESOLVED: missing titleUNRESOLVED: missing authority · UNRESOLVED: missing country · dated UNRESOLVED: missing document date · accessed UNRESOLVED: missing accessed date · source 1
- TAPENTADOL HYDROCHLORIDE SOLUTION [ANI PHARMACEUTICALS, INC.] — US prescribing information (DailyMed SPL)U.S. National Library of Medicine (DailyMed) · US · accessed 2026-08-14 · source 2
- Tapentadol — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 3
- TAPENTADOL — FDA approval record (Drugs@FDA NDA200533)U.S. Food and Drug Administration · US · accessed 2026-08-14 · source 4
- Tapentadol — RxNorm normalized drug concept (RXCUI 787390)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 5
Brand names by country
Single-ingredient Tapentadol names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- Nucynta100 mg, 150 mg, 50 mg, 75 mg, 200 mg, 250 mg · collegium pharmaceutical, inc.
Canada
- NUCYNTA EXTENDED-RELEASE
- NUCYNTA IR